Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.

Breast Cancer Res Treat 2020 Feb 7;180(1):187-195. Epub 2020 Jan 7.

Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.

Purpose: Osteoporosis and fragility fracture are major bone toxicities of aromatase inhibitors (AIs) for postmenopausal hormone receptor-positive breast cancer. Except for a few small studies on bone turnover markers and reduced bone mineral density after AI treatment, data on the associations of bone markers and risk of osteoporosis or fracture from prospective studies are lacking.

Methods: In a prospective study of 1709 women on AIs, two bone turnover markers, BALP and TRACP, and two bone regulatory markers, RANKL and OPG, were measured and examined in relation to risk of osteoporosis and fragility fractures during a median follow-up time of 6.1 years.

Results: Higher levels of BALP and TRACP were both associated with increased risk of osteoporosis and higher BALP/TRACP ratios were associated with lower risk of osteoporosis, but no associations were observed for fracture risk. Higher levels of OPG were associated with increased risk of fracture, whereas higher levels of RANKL were associated with lower risk. As a result, OPG/RANKL ratios were positively associated with fracture risk [hazard ratio (HR) = 2.49, 95% confidence interval (CI) 1.34-4.61]. After controlling for age and fracture history, the associations became non-significant but a suggestive trend remained (HR = 1.80, 95% CI 0.96-3.37).

Conclusion: Our study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05518-zDOI Listing
February 2020

Publication Analysis

Top Keywords

risk osteoporosis
20
osteoporosis fragility
12
higher levels
12
breast cancer
12
risk
10
lower risk
8
fracture risk
8
increased risk
8
prospective study
8
associated increased
8
turnover markers
8
associated lower
8
bone turnover
8
fragility fractures
8
markers risk
8
risk fracture
8
opg/rankl ratios
8
balp tracp
8
bone markers
8
fracture
7

References

(Supplied by CrossRef)

JA Sparano et al.
N Engl J Med 2018

OL Tseng et al.
Ther Adv Musculoskelet Dis 2018

RE Coleman et al.
Lancet Oncol 2007

ML Kwan et al.
PLoS ONE 2014

S Yao et al.
Breast Cancer Res Treat 2017

ML Kwan et al.
Cancer Causes Control 2008

EV McCloskey et al.
Eur J Cancer 2007

PE Goss et al.
J Clin Oncol 2013

RE Coleman et al.
Lancet Oncol 2007

M Rabaglio et al.
Ann Oncol 2009

RC Coombes et al.
Lancet 2007

Similar Publications